Continuous versus intermittent β-lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials.
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Rationale Optimization of β-lactam antibiotic dosing for critically ill patients is an intervention that may improve outcomes in severe sepsis. Objectives In this individual patient data meta-analysis of critically ill patients with severe sepsis, we aimed to compare clinical outcomes of those treated with continuous versus intermittent infusion of β-lactam antibiotics. Methods We identified relevant randomized controlled trials comparing continuous versus intermittent infusion of β-lactam antibiotics in critically ill patients with severe sepsis. We assessed the quality of the studies according to four criteria. We combined individual patient data from studies and assessed data integrity for common baseline demographics and study endpoints, including hospital mortality censored at 30 days and clinical cure. We then determined the pooled estimates of effect and investigated factors associated with hospital mortality in multivariable analysis. Measurements and main results We identified three randomized controlled trials in which researchers recruited a total of 632 patients with severe sepsis. The two groups were well balanced in terms of age, sex, and illness severity. The rates of hospital mortality and clinical cure for the continuous versus intermittent infusion groups were 19.6% versus 26.3% (relative risk, 0.74; 95% confidence interval, 0.56-1.00; P = 0.045) and 55.4% versus 46.3% (relative risk, 1.20; 95% confidence interval, 1.03-1.40; P = 0.021), respectively. In a m…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The desirable effects of empiric antiviral therapy are unknown, and as for other antimicrobial agents there is a risk of undesirable effects (165).”
From Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. (2021) · cites this paper as [165]
In the citing paper
“Two meta-analyses reported similar results supporting reduced short-term mortality (RR 0.70; 95% CI 0.57–0.87) with prolonged infusion of beta-lactams [232, 233].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [232]
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Classification and Regression Trees.
Gordon, A. D., Breiman, L., Friedman, J. H., Olshen, R. A., & Stone, C. J. (1984) · Biometrics · doi:10.2307/2530946 · Cited by 23,522
Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03570.x · Cited by 14,449
APACHE II: A severity of disease classification system
KNAUS, W. A., DRAPER, E. A., WAGNER, D. P., & ZIMMERMAN, J. E. (1985) · Critical Care Medicine · doi:10.1097/00003246-198510000-00009 · Cited by 13,664
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376
Kumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., Suppes, R., Feinstein, D., Zanotti, S., Taiberg, L., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000217961.75225.e9 · Cited by 6,109
Cochrane Handbook for Systematic Reviews of Interventions
Tarsilla, M. (2010) · Journal of MultiDisciplinary Evaluation · doi:10.56645/jmde.v6i14.284 · Cited by 5,178
Cited by
Items 101–200 of 380
Sieswerda, E., Bax, H. I., Hoogerwerf, J. J., de Boer, M. G. J., Boermeester, M. A., Bonten, M. J. M., Dekker, D., van Wijk, R. G., Juffermans, N. P., Kuindersma, M., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07653-3 · Cited by 36
Deutsche Sepsis Gesellschaft e., V., Brunkhorst, F. M., Weigand, M. A., Pletz, M. W., Gastmeier, P., Lemmen, S., Meier‐Hellmann, A., Ragaller, M., Weyland, A., Marx, G., et al. (2020) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-020-00671-6 · Cited by 37
Lan, J., Wu, Z., Wang, X., Wang, Y., Yao, F., Zhao, B., Wang, Y., Chen, J., & Chen, C. (2022) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2022.01.015 · Cited by 34
Gonçalves-Pereira, J., Fernandes, J., Duarte, A. R., & Fernandes, S. M. (2022) · Antibiotics · doi:10.3390/antibiotics11121839 · Cited by 40
“A meta-analysis of the individual data of three prospective studies comparing continuous infusion with intermittent doses of β-lactams [65] unveiled a small but significant benefit of continuous infusion in reducing in-hospital mortality (19.”
MethodThabet, P., Joshi, A., MacDonald, E., Hutton, B., Cheng, W., Stevens, A., & Kanji, S. (2021) · PLOS ONE · doi:10.1371/journal.pone.0244966 · Cited by 29
“Importantly six reviews did not perform subgroup analyses base on study design as these exclusively included RCTs [16, 23, 26, 27, 29, 48].”
BackgroundResultInfluentialJang, S. M., Gharibian, K. N., Lewis, S. J., Fissell, W. H., Tolwani, A., & Mueller, B. A. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1137 · Cited by 33
Pharmacokinetic and pharmacodynamic considerations in antimicrobial therapy for sepsis
Fujii, M., Karumai, T., Yamamoto, R., Kobayashi, E., Ogawa, K., Tounai, M., Lipman, J., & Hayashi, Y. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1750597 · Cited by 32
“045], although clinical cure rates was not different significantly between the arms [95].”
BackgroundSelf-citationExtended and Continuous Infusion of Novel Protected β-Lactam Antibiotics: A Narrative Review
Venuti, F., Trunfio, M., Märtson, A., Lipani, F., Audagnotto, S., Perri, G. D., & Calcagno, A. (2023) · Drugs · doi:10.1007/s40265-023-01893-6 · Cited by 32
“Three randomized control trials (RCTs) were included in a meta-analysis to compare continuous and intermittent infusion of β-lactams [82].”
BackgroundHeffernan, A. J., Sime, F. B., Taccone, F. S., & Roberts, J. A. (2018) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000494 · Cited by 30
Self-citationD’Huart, É., Vigneron, J., & Demoré, B. (2019) · Pharmaceutical Technology in Hospital Pharmacy · doi:10.1515/pthp-2019-0005 · Cited by 28
Tabah, A., Lipman, J., Barbier, F., Buetti, N., Timsit, J., & on behalf of the ESCMID Study Group for Infections in Critically Ill Patients—ESGCIP (2022) · Antibiotics · doi:10.3390/antibiotics11030362 · Cited by 39
“Combination of daptomycin plus ceftaroline as rescue therapy for refractory MRSA BSIs has been reported [65].”
BackgroundSelf-citationNew guidelines for nosocomial pneumonia
Metersky, M. L., & Kalil, A. C. (2017) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000367 · Cited by 33
Skhirtladze‐Dworschak, K., Hutschala, D., Reining, G., Dittrich, P., Bartunek, A. E., Dworschak, M., & Tschernko, E. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13865 · Cited by 28
Wu, C., Su, Y., Wu, K.-S., Wu, T., & Yang, C. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13301 · Cited by 27
Maimongkol, P., Yonwises, W., Anugulruengkitt, S., Sophonphan, J., Treyaprasert, W., & Wacharachaisurapol, N. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.04.052 · Cited by 27
Addition of probenecid to oral β-lactam antibiotics: a systematic review and meta-analysis
Wilson, R. C., Arkell, P., Riezk, A., Gilchrist, M. J., Wheeler, G., Hope, W. W., Holmes, A. H., & Rawson, T. M. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac200 · Cited by 31
Dilworth, T. J., Schulz, L. T., Micek, S. T., Kollef, M. H., & Rose, W. E. (2022) · Critical Care Explorations · doi:10.1097/cce.0000000000000726 · Cited by 33
Mader, M. M.-D., Czorlich, P., König, C., Fuhrmann, V., Kluge, S., Westphal, M., & Grensemann, J. (2018) · Acta Neurochirurgica · doi:10.1007/s00701-018-3680-z · Cited by 30
Rules of anti-infection therapy for sepsis and septic shock
Zhou, X. Q., Su, L., Zhang, J., Liu, D., & Long, Y. (2019) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000101 · Cited by 29
Brinkmann, A., Röhr, A. C., Koeberer, A., Fuchs, T., Preisenberger, J., Krüger, W. A., & Frey, O. R. (2016) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-016-0213-5 · Cited by 31
Kalaria, S. N., Gopalakrishnan, M., & Heil, E. L. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02093-19 · Cited by 26
“These findings are similar to those of studies comparing extended infusions and intermittent dosing of various -lactam antibiotics (12, 15, 16).”
BackgroundResultCojutti, P. G., Gatti, M., Rinaldi, M., Tonetti, T., Laici, C., Mega, C., Siniscalchi, A., Giannella, M., Viale, P., & Pea, F. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.781892 · Cited by 25
Mirjalili, M., Zand, F., Karimzadeh, I., Masjedi, M., Sabetian, G., Mirzaei, E., & Vazin, A. (2022) · Journal of Critical Care · doi:10.1016/j.jcrc.2022.154170 · Cited by 28
Miglis, C. M., Rhodes, N. J., Kuti, J. L., Nicolau, D. P., Wart, S. A. V., & Scheetz, M. H. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.04.023 · Cited by 25
Chiriac, U., Richter, D., Frey, O. R., Röhr, A. C., Helbig, S., Preisenberger, J., Hagel, S., Roberts, J. A., Weigand, M. A., & Brinkmann, A. (2021) · Antibiotics · doi:10.3390/antibiotics10060667 · Cited by 28
“Considering the association of potentially toxic serum concentration (f T>4× MIC) and a higher mortality [13,14,23], this study strongly supports the present recommendations on personalized antibiotic dosing [3,18,31,43] including continuous application of ß-lactams [20,21,31,32] in critically ill patients with sepsis…”
ResultSelf-citationOptimal infusion rate in antimicrobial therapy: explosion of evidence in the last five years
Zhu, L., & Zhou, Q. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s167616 · Cited by 24
“Roberts et al 5 performed a meta-analysis of 632 critically ill patients with severe sepsis from three randomized trials, and concluded that administration of β -lactam antibiotics by continuous infusion was associated with decreased hospital mortality (19.6% vs 26.3%; relative risk = 0.74; P = 0.045) and improved cli…”
InfluentialGuilhaumou, R., Chevrier, C., Setti, J.-L., Jouve, É., Marsot, A., Julian, N., Blin, O., Simeone, P., Lagier, D., Mokart, D., et al. (2023) · Antibiotics · doi:10.3390/antibiotics12081289 · Cited by 25
Practical Lessons on Antimicrobial Therapy for Critically Ill Patients
Cusack, R. A. F., Little, E., & Martín‐Loeches, I. (2024) · Antibiotics · doi:10.3390/antibiotics13020162 · Cited by 28
“Others specifically addressed short-term (30-day) mortality and clinical cure and did infer some benefit [113,114].”
BackgroundKaraba, S. M., Cosgrove, S. E., Lee, J. H., Fiawoo, S., Heil, E. L., Quartuccio, K. S., Shihadeh, K. C., & Tamma, P. D. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.18234 · Cited by 27
Thibault, C., Lavigne, J. R., Litalien, C., Kassir, N., Théorêt, Y., & Autmizguine, J. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01260-19 · Cited by 23
“Extended TZP infusions are associated with better PD target attainment and decreased mortality (6, 7), improvement in clinical cure (8–10), and cost reductions in adults (11, 12).”
BackgroundRestituto, D. F., Luque, S., Benítez-Cano, A., Sorlí, L., Montero, M., de Antonio-Cuscó, M., Prim, N., Vega, V., Horcajada, J. P., & Grau, S. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac439 · Cited by 22
Rawson, T. M., Antcliffe, D. B., Wilson, R. C., Abdolrasouli, A., & Moore, L. S. P. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s390946 · Cited by 26
“To address observed variability in antimicrobial PK/PD, prolonged or continuous infusion of beta-lactam and glycopeptide antibiotics is often recommended to ensure optimised targeted attainment.(63,64)”
BackgroundBrinkmann, A., Röhr, A. C., Frey, O. R., Krüger, W. A., Brenner, T., Richter, D., Bodmann, K. ‐., Kresken, M., & Grabein, B. (2018) · Der Anaesthesist · doi:10.1007/s00101-018-0512-8 · Cited by 25
Cojutti, P. G., Maximova, N., Schillani, G., Hope, W. W., & Pea, F. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz065 · Cited by 21
Hui, L.-A., Bodolea, C., Vlase, L., Hirişcău, E. I., & Popa, A. (2022) · Antibiotics · doi:10.3390/antibiotics11040436 · Cited by 21
“They compared clinical outcomes after CI with II of β-lactam antibiotics, and concluded that CI of β-lactam antibiotics was associated with lower hospital mortality at 30 days and higher clinical cure compared to II [15].”
ResultSanz-Codina, M., Gatti, M., Troisi, C., Fornaro, G., Pasquini, Z. A. I., Trapani, F., Zanoni, A., Caramelli, F., Viale, P., & Pea, F. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081585 · Cited by 22
“CI administration has been shown to be superior compared to intermittent infusion in attaining a given pharmacodynamic (PD) target of efficacy and in improving clinical outcomes with beta-lactams among critically ill patients [14,15].”
BackgroundExtracorporeal Membrane Oxygenation for Septic Shock in Children
Melnikov, G., Grabowski, S., & Broman, L. M. (2021) · ASAIO Journal · doi:10.1097/mat.0000000000001464 · Cited by 19
“29 Bi-ventricular dysfunction 10 (32) 3 (30) 7 (33) 1.”
Cojutti, P. G., Morandin, E., Baraldo, M., & Pea, F. (2021) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2021.106408 · Cited by 21
Zhao, Y., Zang, B., & Wang, Q. (2024) · Annals of Intensive Care · doi:10.1186/s13613-024-01263-9 · Cited by 21
Extended Infusion of Beta-Lactams Is Associated With Improved Outcomes in Pediatric Patients
Zembles, T. N., Schortemeyer, R. L., Kuhn, E. M., Bushee, G. M., Thompson, N. E., & Mitchell, M. L. (2021) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-26.2.187 · Cited by 24
Chongcharoenyanon, T., Wacharachaisurapol, N., Anugulruengkitt, S., Maimongkol, P., Anunsittichai, O., Sophonphan, J., Chatsuwan, T., & Puthanakit, T. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.05.044 · Cited by 19
Hyun, D., Seo, J., Lee, S. Y., Ahn, J. H., Hong, S., Lim, C., Koh, Y., & Huh, J. W. (2022) · Antibiotics · doi:10.3390/antibiotics11111508 · Cited by 21
“However, a metaanalysis of prospective clinical studies for severe sepsis demonstrated the superiority of continuous infusion over intermittent infusion in terms of patient survival [14].”
BackgroundAdäquate Antiinfektivatherapie: Bedeutung der individuellen Dosierung und Applikation
Brinkmann, A., Röhr, A. C., Koeberer, A., Fuchs, T., Krüger, W. A., König, C., Richter, D., Weigand, M. A., & Frey, O. R. (2018) · Der Anaesthesist · doi:10.1007/s00101-018-0443-4 · Cited by 19
Costenaro, P., Minotti, C., Cuppini, E., Barbieri, E., Giaquinto, C., & Donà, D. (2020) · Antibiotics · doi:10.3390/antibiotics9060329 · Cited by 21
Cojutti, P. G., Pai, M. P., Tonetti, T., Siniscalchi, A., Viale, P., & Pea, F. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01404-23 · Cited by 17
Pathogenic, immunologic, and clinical aspects of sepsis – update 2016
Uhle, F., Chousterman, B. G., Grützmann, R., Brenner, T., & Weber, G. F. (2016) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2016.1224971 · Cited by 22
“the benefit of a continuous infusion over an intermittent application, elucidating the multidimensional complexity of anti-infective treatment [118].”
BackgroundCarbapenem-Resistant Enterobacteriaceae in Solid Organ Transplantation: Management Principles
Smibert, O. C., Satlin, M. J., Nellore, A., & Peleg, A. Y. (2019) · Current Infectious Disease Reports · doi:10.1007/s11908-019-0679-4 · Cited by 18
Antibiotic treatment in patients with sepsis: a narrative review
Plata-Menchaca, E. P., Ferrer, R., Ruiz‐Rodríguez, J. C., Morais, R., & Póvoa, P. M. S. R. (2020) · Hospital Practice · doi:10.1080/21548331.2020.1791541 · Cited by 19
Dried Plasma Spot Based LC–MS/MS Method for Monitoring of Meropenem in the Blood of Treated Patients
Cao, H., Jiang, Y., Wang, S., Cao, H., Li, Y., & Huang, J. (2022) · Molecules · doi:10.3390/molecules27061991 · Cited by 17
Why We May Need Higher Doses of Beta-Lactam Antibiotics: Introducing the ‘Maximum Tolerable Dose’
Dhaese, S. A. M., Hoste, E. A. J., & Waele, J. J. D. (2022) · Antibiotics · doi:10.3390/antibiotics11070889 · Cited by 17
Chiriac, U., Richter, D., Frey, O. R., Röhr, A. C., Helbig, S., Hagel, S., Liebchen, U., Weigand, M. A., & Brinkmann, A. (2023) · Antibiotics · doi:10.3390/antibiotics12071112 · Cited by 20
Barker, C. I. S., Kipper, K., Lonsdale, D., Wright, K., Thompson, G., Kim, M., Turner, M. A., Johnston, A. E., Sharland, M., & Standing, J. F. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad196 · Cited by 17
State of the Management of Infections Caused by Multidrug-Resistant Gram-Negative Organisms
Yassin, A., Huralska, M., Pogue, J. M., Dixit, D., Sawyer, R. G., & Kaye, K. S. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad499 · Cited by 17
Budai, K. A., Tímár, Á. E., Obeidat, M., Máté, V., Nagy, R., Harnos, A., Kiss‐Dala, S., Hegyi, P., Garami, M., Hankó, B., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102293 · Cited by 18
“48,49 47 EI was preferred for more seriously ill patients with pneumonia; the clinical cure rate was higher in patients with APACHE II scores ≥ 15 receiving EI vs. SI.”
BackgroundRiccobene, T. A., Carrothers, T. J., Knebel, W., Raber, S. R., & Chan, P. L. S. (2021) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.907 · Cited by 16
Timsit, J., Pilmis, B., & Zahar, J. (2017) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0037-1603112 · Cited by 21
Leegwater, E., Wewerinke, L., de Grauw, A. M., van Veen, M., Storm, B. N., & Kruizinga, M. D. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01230-w · Cited by 18
“In critically ill adults, this also led to improved clinical and microbiological outcomes [5, 6, 31].”
BackgroundGuidelines for Antibiotics Prescription in Critically Ill Patients
Chaudhry, D., Desai, M., Gupta, M., Mohan, A., Mehta, Y. B., Sengar, M., Govil, D., Hegde, A. V., Rungta, N., Mittal, S., et al. (2024) · Indian Journal of Critical Care Medicine · doi:10.5005/jp-journals-10071-24677 · Cited by 20
Abdul-Aziz, M. H., Driver, E., Lipman, J., & Roberts, J. A. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1484452 · Cited by 15
“Additionally, by exploiting the relevant PK/PD characteristics of a particular antibiotic, a clinician would be able to apply alternative dosing strategies in these populations that ultimately increase the likelihood of treatment success as well asminimize the emergence of bacterial resistance [26,27].”
BackgroundSelf-citationOnorato, L., Monari, C., Capuano, S., Grimaldi, P., & Coppola, N. (2022) · Antibiotics · doi:10.3390/antibiotics11020232 · Cited by 19
“There is a growing body of evidence demonstrating the superiority of these administration strategies over intermittent infusion in critically ill patients [60].”
BackgroundLi, X., Long, Y., Wu, G., Li, R., Zhou, M., He, A., & Jiang, Z. (2023) · Annals of Intensive Care · doi:10.1186/s13613-023-01222-w · Cited by 19
“The results of this study are consistent with most previous similar studies showing that prolonged intravenous infusion of beta-lactam antibiotics in patients with severe infection are associated with improved clinical outcomes [12, 13, 29–31].”
Olbrisch, K., Kisch, T., Thern, J., Kramme, E., Rupp, J., Graf, T., Wicha, S. G., Mailänder, P., & Raasch, W. (2018) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-018-1573-6 · Cited by 15
Aardema, H., Bult, W., van Hateren, K., Dieperink, W., Touw, D. J., Alffenaar, J. C., & Zijlstra, J. G. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz463 · Cited by 19
The comparative risk of acute kidney injury of vancomycin relative to other common antibiotics
Gaggl, M., Pate, V., Stürmer, T., Kshirsagar, A. V., & Layton, J. B. (2020) · Scientific Reports · doi:10.1038/s41598-020-73687-9 · Cited by 16
Bella, S. D., Beovič, B., Fabbiani, M., Valentini, M., & Luzzati, R. (2020) · Antibiotics · doi:10.3390/antibiotics9070398 · Cited by 17
“In addition, the literature data support the administration of beta-lactam antibiotics through continuous infusion for both increasing antibacterial activity and reducing sepsis-associated mortality [11].”
BackgroundAntibiotic dosing for multidrug-resistant pathogen pneumonia
Abdul-Aziz, M. H., Lipman, J., & Roberts, J. A. (2016) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000348 · Cited by 17
Self-citationWeber, N., Jackson, K., McWhinney, B. C., Ungerer, J. P. J., Kennedy, G., Lipman, J., & Roberts, J. A. (2019) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2019.02.014 · Cited by 14
Self-citationRecent Progress and Novel Perspectives of Electrochemical Sensor for Cephalosporins Detection
Wang, Q., Wang, D., Wang, J., Cui, Y., & Xu, H. (2019) · International Journal of Electrochemical Science · doi:10.20964/2019.09.15 · Cited by 14
Sumi, C. D., Heffernan, A. J., Naicker, S., Islam, K., Cottrell, K., Wallis, S. C., Lipman, J., Harris, P. N. A., Sime, F. B., & Roberts, J. A. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa211 · Cited by 14
Self-citationEisert, A., Lanckohr, C., Frey, J., Frey, O. R., Wicha, S. G., Horn, D., Ellger, B., Schuerholz, T., Marx, G., & Simon, T.-P. (2021) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2021.106289 · Cited by 15
Richter, D., Dietrich, M., Lalev, L. D., Schmitt, F. C. F., Fiedler, M. O., Bruckner, T. M., Störzinger, D., Chiriac, U., Klein, S., Hackert, T., et al. (2021) · Antibiotics · doi:10.3390/antibiotics10060687 · Cited by 16
“Previous investigations already suggested lower mortality rates and better clinical outcome using extended infusions in adults [23-25, 34-36] and pediatric patients [37].”
ResultBusse, D., Simon, P., Schmitt, L., Petroff, D., Dorn, C., Dietrich, A., Zeitlinger, M. A., Huisinga, W., Michelet, R., Wrigge, H., et al. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01070-6 · Cited by 14
“These results indicate that the reported superiority of prolonged and continuous infusions (given infusion bags are prepared accordingly to account for the chemical instability of meropenem [44]) versus short-term infusion, regarding mortality and duration of therapy [45, 46] may well also apply to obese patients.”
BackgroundCoyne, A. J. K., Al‐Shaer, M. H., Casapao, A. M., Venugopalan, V., Isache, C. L., Ferreira, J., & Jankowski, C. A. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00646-22 · Cited by 14
“001 All-cause mortality during BLA therapy 12 (13) 21 (20) 0.”
Westermann, I., Gastine, S., Müller, C., Rudolph, W., Peters, F. T., Bloos, F., Pletz, M. W., & Hagel, S. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14846 · Cited by 16
“Furthermore, a recent meta-analysis found decreased hospital mortality in patients treated with CI of β-lactams, including meropenem.(13) In addition, the use of supportive extracorporeal therapies, such as continuous renal replacement therapy, further complicates the PK behaviour of antibiotics.”
BackgroundLee, D. H., Kim, H.-S., Park, S., Kim, H. I., Lee, S., & Kim, Y.-K. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111861 · Cited by 14
“Previous studies have reported the positive impact of prolonged meropenem infusion on clinical outcomes such as hospital mortality in critically ill patients [26,27].”
BackgroundDräger, S., von Rotz, M., Labhardt, N. D., Siegemund, M., Rentsch, K., Osthoff, M. F., & Franzeck, F. C. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad143 · Cited by 19
“…that the free drug concentration ( f T) of β -lactam antibiotics is maintained above the minimal inhibitory concentration (MIC) of the underlying path-ogen during the entire dosing interval (100% f T > MIC ) to improve clinical outcome [1, 2, 10–14] and to enhance bacterial killing [15–18].”
Jenkins, A., Jamieson, C., & Santillo, M. (2023) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2023-003855 · Cited by 15
“10 The meta-analysis of trials looking at extended or continuous infusions of a carbapenem or piperacillin-tazobactam conducted by Falagas et al found CI resulted in lower mortality than short-term infusions.”
BackgroundControversies and advances in the management of ventilator associated pneumonia
Roberts, K. L., Micek, S. T., Juang, P., & Kollef, M. H. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1378574 · Cited by 16
“not achieve conservative PK/PD targets (50% f T>MIC) with contemporary antibiotic dosing strategies [68].”
BackgroundDerendorf, H., Heinrichs, T., Reimers, T., Lebert, C., & Brinkmann, A. (2020) · GMS infectious diseases · doi:10.3205/id000061 · Cited by 18
Petersson, J., Giske, C. G., & Eliasson, E. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02029-20 · Cited by 14
Aardema, H., Panday, P. V. N., Wessels, A. M. A., van Hateren, K., Dieperink, W., Kosterink, J. G. W., Alffenaar, J. C., & Zijlstra, J. G. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.02.020 · Cited by 16
“Although high-quality randomised trials showing a survival benefit are still lacking, in a recent meta-analysis of individual patient data from three randomised trials, treatment with -lactam antibiotics by continuous infusion was associated with lower mortality compared with intermittent dosing in critically ill pat…”
BackgroundBarton, G. J., Morecroft, C. W., & Henney, N. C. (2019) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-019-00938-9 · Cited by 13
Loeuille, G., Vigneron, J., D’Huart, É., Charmillon, A., & Demoré, B. (2021) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2021-002935 · Cited by 13
Personalised beta-lactam therapy: basic principles and practical approach
Streit, F., Perl, T., Schulze, M. H., & Binder, L. (2016) · Journal of Laboratory Medicine · doi:10.1515/labmed-2016-0050 · Cited by 12
Antibiotic Combination Therapy for Patients With Gram-Negative Septic Shock
Kalil, A. C. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002677 · Cited by 12
Comparing current US and European guidelines for nosocomial pneumonia
Kelly, D. N., & Martín‐Loeches, I. (2018) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000559 · Cited by 12
Laporte-Amargós, J., Gudiol, C., Arnán, M., Puerta‐Alcalde, P., Carmona-Torre, F., Huguet, M., Albasanz‐Puig, A., Parody, R., García‐Vidal, C., del Pozo, J. L., et al. (2020) · Trials · doi:10.1186/s13063-020-04323-0 · Cited by 12
Larcher, R., Laffont-Lozes, P., Naciri, T., Bourgeois, P.-M., Gandon, C., Magnan, C., Pantel, A., & Sotto, A. (2023) · Infection · doi:10.1007/s15010-023-02055-2 · Cited by 13
“Therefore, CI appears to be a promising dosing strategy to increase the likelihood of achieving the most optimized pharmacokinetic/pharmacodynamic (PK/PD) target [4, 8].”
BackgroundSulaiman, H., Abdul-Aziz, M. H., & Roberts, J. A. (2017) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0037-1602716 · Cited by 13
Self-citationZhou, Q., He, B., Shen, N., Liang, Y., & Sun, L. (2017) · Drugs & Aging · doi:10.1007/s40266-016-0431-9 · Cited by 14
Arain, S. I., Khalawi, F., Parakkal, S. A., AlHamad, H. S., Thorakkattil, S. A., Alghashmari, F. F. J., Alharbi, B. A., Bakhashwain, N., Alzawad, W. M., & Al‐Homoud, A. H. (2023) · Antibiotics · doi:10.3390/antibiotics12071192 · Cited by 13
Evaluation of continuous ampicillin/sulbactam infusion in critically ill patients
Passon, S. G., Schmidt, A. R., Wittmann, M., Velten, M., & Baehner, T. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121567 · Cited by 12
Prinz, C., Streit, F., Schumann, C., Dudakova, A., Lanckohr, C., Schanz, J., Bohn, M., Groß, U., Meissner, K., Moerer, O., et al. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01257-8 · Cited by 12
“It is well established that these metabolic or pharmacokinetic alterations can cause widely divergent plasma antimicrobial concentrations after standard doses [29].”
BackgroundChan, J. D., Dellit, T. H., & Lynch, J. B. (2017) · Journal of Intensive Care Medicine · doi:10.1177/0885066617708756 · Cited by 11
Inhaled antibiotics for the treatment of pneumonia
Schreiber, M. P., & Shorr, A. F. (2018) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000557 · Cited by 11
“necessarily, focused on the development and testing of novel new agents whereas other approaches have emphasized the optimization of pharmacodynamics and pharmacokinetics at the bedside [8].”
Liebchen, U., Salletmeier, H., Kallee, S., Scharf, C., Hübner, L., Weber, A., & Zöller, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-96744-3 · Cited by 12
Sartelli, M., Cristini, F., Coccolini, F., Labricciosa, F. M., Siquini, W., & Catena, F. (2022) · Antibiotics · doi:10.3390/antibiotics11101394 · Cited by 12
“Although there is insufficient evidence to reach definitive strong conclusions, two meta-analyses have demonstrated reduced short-term mortality with prolonged infusion of beta-lactam agents in critically ill patients [99,100].”
BackgroundAntimicrobial prophylaxis is critical for preventing surgical site infection
Duclos, G., Zieleskiewicz, L., & Léone, M. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.08.81 · Cited by 11
Individualized antibiotic therapy in the treatment of severe infections
Annoni, F., Grimaldi, D., & Taccone, F. S. (2019) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1696192 · Cited by 12
“tages over standard regimens remains to be clarified [52].”
BackgroundPharmacokinetics/pharmacodynamics of ceftobiprole in patients on extracorporeal membrane oxygenation
Coppens, A., Zahr, N., Chommeloux, J., Bleibtreu, A., Hékimian, G., de Chambrun, M. P., Lefèvre, L., Schmidt, M., Robert, J., Junot, H., et al. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.106765 · Cited by 11
Metadata
- Authors
- Roberts, J. A., Abdul-Aziz, M.-H., Davis, J. S., Dulhunty, J. M., Cotta, M. O., Myburgh, J., Bellomo, R., & Lipman, J.
- Affiliations
- The University of Queensland (AU)
- International Islamic University Malaysia (MY)
- John Hunter Hospital (AU)
- Redcliffe Hospital (AU)
- The George Institute for Global Health (GB)
- Austin Hospital (AU)
- Department of Intensive Care Medicine and
- Corresponding author
- Roberts, Jason A.
- ORCID
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-09
- Volume
- 194
- Issue
- 6
- Pages
- 681-691
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2298261704
- Cited by
- 379
- References
- 46
- Citations by year
- 2026: 11 · 2025: 18 · 2024: 45 · 2023: 51 · 2022: 37 · 2021: 44 · 2020: 43 · 2019: 38 · 2018: 38 · 2017: 39 · 2016: 15
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Respiratory and Critical Care Medicine (publishedVersion)
- PubMed (publishedVersion)
- NOVA (University of Newcastle Australia) (submittedVersion)
- Funders
- National Health and Medical Research Council of Australia (APP1048652)
- Australian National Health and Medical Research Council (APP1099452)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
- Keywords
- severe sepsis, beta-lactam antibiotics, continuous infusion, intermittent infusion, antibiotic dosing, in-hospital mortality, clinical cure, critically ill patients, APACHE II score, renal replacement therapy, non-fermenting Gram-negative bacilli
- MeSH terms
- Aged, Anti-Bacterial Agents, Drug Administration Schedule, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Proportional Hazards Models, Randomized Controlled Trials as Topic, Sepsis, beta-Lactams
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.